Agilent and Incyte Collaborate on Development of CDx in Hematology and Oncology

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - stock.adobe.com

Agilent Technologies has revealed in a Jan. 30, 2024 press release that it has entered into an agreement with Incyte for the development of companion diagnostics (CDx) programs to support Incyte’s hematology and oncology portfolio.

According to the press release, the agreement will allow both companies to work together on CDx development programs, enabling Agilent to continue to expand its companion diagnostics portfolio with novel biomarkers while also allowing Incyte to leverage Agilent’s expertise across a range of functions to support clinical trials. Additionally, Incyte will take advantage of Agilent’s experience to achieve potential registration and commercialization of CDx in both the United States and Europe.

“Leveraging the power of companion diagnostics, we are strategically transforming the treatment paradigm for a broad spectrum of cancers,” said Paul Beresford, vice president and general manager of Agilent’s Companion Diagnostics Division, in the press release. “By working together, Agilent and Incyte hope to expedite the development of innovative precision medicine products, potentially paving the way for enhanced patient health outcomes.”

“Agilent’s expertise in the development of companion diagnostics is impressive, as is their regulatory and commercialization record,” added Jeff Jackson, group vice president of Translational Medicine at Incyte, in the press release. “We are excited about the collaboration and look forward to working together to innovate in support of patients.”

Companion diagnostics are used to evaluate expression of biomarkers and can identify patients that are more likely to respond to treatment with targeted therapeutics. As a result of their use and ability to inform treatment decisions, the companion diagnostics market is expected to grow in the near future.

Source: Agilent